The Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Whitehawk is a clinical-stage oncology therapeutics company focused on antibody-drug conjugate (ADC) cancer treatments, and its filings offer insight into financial results, development plans and corporate activities related to this strategy.
Among the key documents available are current reports on Form 8-K, which Whitehawk has used to furnish press releases announcing quarterly financial results and recent highlights. These filings reference information such as research and development spending, progress toward Investigational New Drug (IND) submissions for ADC programs like HWK-007 and HWK-016, and updates on the company’s three-asset ADC portfolio targeting PTK7, MUC16 and SEZ6.
On this page, users can also locate Whitehawk’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain more detailed discussions of the company’s oncology pipeline, risk factors, and financial condition. For investors interested in governance and compensation matters, proxy materials and related filings can provide additional context on board and executive oversight of the ADC development strategy.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major updates without having to parse every page. Real-time updates from the SEC’s EDGAR system ensure that new WHWK filings, including future 10-Ks, 10-Qs and 8-Ks, appear promptly. Users can also review insider transaction reports on Form 4, when available, to see reported trades by directors and officers.
Together, these resources give a structured view of how Whitehawk reports its financial performance, clinical progress and corporate decisions to regulators and the market.
Whitehawk Therapeutics, Inc. (WHWK) reported equity compensation grants to its Chief Technical Operations Officer, Bryan Ball. On September 15, 2026, he received a stock option for 91,633 shares of common stock at an exercise price of $4.09 per share, expiring on September 15, 2036. The option vests 25% on the one-year anniversary of the Vesting Commencement Date of September 15, 2026, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. On the same date, he also received 91,633 restricted stock units, each representing one share of common stock, vesting 25% on the first anniversary of the Vesting Commencement Date and 25% on each of the next three anniversaries, also conditioned on continued service. No Rule 10b5-1 trading plan is reported for these awards.
Whitehawk Therapeutics, Inc. (WHWK) reported that director Vijay K. Iyengar received a stock option grant on September 9, 2026. The award covers 76,080 shares of common stock at an exercise price of $4.19 per share, expiring on September 9, 2036, and is held directly.
According to the award terms, the option vests in 36 equal monthly installments, with one thirty-sixth of the shares vesting each month so that all shares are fully vested on the three-year anniversary of the September 9, 2026 grant date. No Rule 10b5-1 trading plan is reported for this grant.
Whitehawk Therapeutics, Inc. (WHWK) reported an initial statement of beneficial ownership for Vijay K. Iyengar, who is identified as a director of the company. The filing reports no equity transactions, derivative positions, or holdings as of the Form 3 reporting date.
Whitehawk Therapeutics, Inc. (WHWK) expanded its board of directors from nine to ten members and appointed Vijay Iyengar, M.D. as a Class III director, effective September 9, 2026, with a term expiring at the 2029 annual meeting of stockholders. Dr. Iyengar is a seasoned oncology executive, having held senior global medical affairs, strategy, corporate development and commercial roles at Incyte and Novartis, and earlier experience at McKinsey. As a non-employee director, he will receive the standard outside director cash retainer and an initial stock option grant that vests monthly over three years. Whitehawk highlights that his background supports its focus on developing antibody-drug conjugate cancer treatments and advancing its clinical-stage ADC portfolio.
Whitehawk Therapeutics, Inc. reported an updated large-shareholder position by OrbiMed entities. OrbiMed Advisors LLC and OrbiMed Genesis GP LLC each report beneficial ownership of 3,934,296 shares of Whitehawk Therapeutics common stock, representing 7.3% of the outstanding class as of June 30, 2026.
The OrbiMed entities report no sole voting or dispositive power over these shares, but shared voting and shared dispositive power over 3,934,296 shares. The holdings are maintained on behalf of other persons who have the right to receive dividends or sale proceeds, while OrbiMed Advisors LLC exercises investment and voting power through a management committee whose members disclaim beneficial ownership.
Whitehawk Therapeutics, Inc. is the subject of an amended Schedule 13G filing by a group of Ally Bridge–affiliated investment entities and Fan Yu. Based on 57,009,010 common shares outstanding as of June 30, 2026, the group reports beneficial ownership of 5,679,253 shares of common stock, representing 9.4% of the class. This total includes 817,939 shares held by Ally Bridge MedAlpha Master Fund L.P., 1,651,388 shares held by ABG V-SIV Limited, and 3,209,926 shares issuable upon exercise of currently exercisable warrants held by ABG V-SIV Limited, which are subject to a 9.99% beneficial ownership limitation on exercise. ABG Innovation SO Limited no longer holds shares in the issuer. Control and management relationships among the reporting entities ultimately trace to Fan Yu, who, together with the entities, may be deemed to share beneficial ownership but disclaims beneficial ownership of the securities.
Whitehawk Therapeutics, Inc. reported a net loss of $16.6 million for the quarter and $38.8 million for the six months ended June 30, 2026, with no product revenue following the March 2025 divestiture of its FYARRO business. Operating expenses for the first half totaled $41.6 million, driven mainly by $30.1 million in research and development and $11.5 million in selling, general and administrative costs.
Other income for the first half of 2026 was $2.8 million, primarily interest on the company’s investment portfolio. After the FYARRO sale, Whitehawk is focused on a portfolio of three next-generation antibody drug conjugates licensed from WuXi Biologics, with two clinical and one preclinical-stage candidates.
Liquidity is strong: at June 30, 2026, cash, cash equivalents and short-term investments were $190.0 million, total liabilities were $11.1 million, and stockholders’ equity was $182.9 million. Net cash used in operating activities was $36.7 million for the first half, largely offset by $81.8 million in net proceeds from a May 2026 PIPE financing. Management states existing funds are expected to support operations into the second half of 2028.
Whitehawk Therapeutics, a clinical-stage oncology company focused on antibody drug conjugates, reported second quarter 2026 results. Cash, cash equivalents and short-term investments were $190.0 million as of June 30, 2026, up from $145.7 million at December 31, 2025, and are expected to fund operations into 2H 2028.
The company continued enrolling patients in Phase 1 trials of HWK-007 and HWK-016 and plans to initiate a Phase 1 study of HWK-206 in small-cell lung cancer and neuroendocrine tumors in Q3 2026, with initial Phase 1 data for HWK-007 and HWK-016 anticipated in 1H 2027. Whitehawk expanded its platform through an option agreement with Hangzhou DAC for CPT113-based ADCs and a global collaboration with Biocytogen to access up to five bispecific antibodies using the RenLite platform.
Research and development expenses were $12.9 million for the quarter, compared with $48.8 million a year earlier, when results included a $38.0 million up-front license fee to WuXi Biologics. Net loss was $16.6 million, or $0.20 per share, versus a net loss of $52.6 million, or $0.76 per share, in the prior-year quarter.
Whitehawk Therapeutics, Inc. director Anupam Dalal reported two equity-related acquisitions. He was granted 38,040 stock options with an exercise price of $4.16 per share, expiring in 2036; all options vest on the earlier of one year from the June 12, 2026 grant date or immediately before the next annual stockholders’ meeting, subject to continued service.
Dalal also reported an indirect acquisition of 1,275,510 shares of common stock at $3.92 per share, held through Acuta Capital Fund, LP and Acuta Opportunity Fund, LP, bringing his reported indirect holdings via these funds to 4,685,912 shares. He has voting and investment authority over these fund holdings but disclaims beneficial ownership except to the extent of his pecuniary interest. Separately, he holds 1,130 common shares directly.
Whitehawk Therapeutics director Baiteng Zhao received a grant of stock options as compensation. On the grant date, Zhao was awarded options for 38,040 shares of common stock at an exercise price of $4.16 per share, expiring on June 12, 2036. All options vest 100% after about one year or just before the next annual stockholder meeting, as long as Zhao continues serving the company.